Skip to main content
. 2017 Nov 12;23:5389–5395. doi: 10.12659/MSM.903927

Figure 3.

Figure 3

Overall survival analysis in stage II and III CRC patients treated with oxaliplatin-based chemotherapy according to methylation status of RASSF1A. Patients without RASSF1A methylation had a favorable prognosis, compared with those with methylation (31.66 months versus 25.90 months, log rank test, p=0.006).